A case of scleroderma in a woman with carcinoid syndrome is described and the similarities between our case and those in the literature are reviewed. The carcinoid tumours were all of midgut origin and liver metastases were present. All subsequently developed fibrotic heart disease and none had clinical features or autoantibodies suggestive of systemic sclerosis. The association between carcinoid syndrome and particular features of scleroderma is likely to be more than fortuitous.
Cutaneous scleroderma is part of a spectrum of diseases characterised by skin fibrosis and loss of elasticity. The pathogenesis is unclear. Carcinoid syndrome is a result of secretory products released by a carcinoid tumour, usually a gut primary with liver metastases. The secretory products of mid gut carcinoid tumours may be implicated in the pathogenesis of cutaneous scleroderma associated with carcinoid syndrome.
Case report
A 48-year-old woman presented in May 1983 complaining of intermittent diarrhoea and weight loss of 14 lbs over the preceding year. On direct questioning she admitted to episodes of facial flushing occurring over the previous 18 months. On examination she had facial telangiectasia, a cyanotic tinge over the cheeks and forehead, and four finger breath hepatomegaly. Investigations revealed a raised 24 hour 5-hydroxyindoleacetic acid level of 720 ftmol (normal less than 50 gmol). Fine needle biopsy of a mass in the right lobe of the liver was consistent with a diagnosis of metastatic carcinoid.
Treatment was commenced with the oral serotonin antagonist, cyproheptadine, and subsequently with ketanserin and p-chlorophenylalanine. Her symptoms were not controlled and hepatic artery embolisation was undertaken on four occasions over the next two years. Each procedure resulted in symptomatic relief for approximately six months. The patient developed right heart failure due to tricuspid and pulmonary stenosis in September 1986 and responded well to balloon valvuloplasty. The original symptoms of carcinoid syndrome returned in November 1986 and treatment was started with the long-acting somatostatin analogue Octreotide (100 ig 8 hourly) which the patient administered by subcutaneous injection.
In November 1988 thickened and slightly tender patches of skin developed over both thighs (figure 1). Clinically this was thought to be localised scleroderma. Skin biopsy ( figure 2) showing collagenisation of the recticular dermis extending below the sweat glands, with a mild chronic inflammatory infiltrate around the sweat glands and vessels at the dermal-fat junction, confirmed the diagnosis. These cases are similar: scleroderma first developed in the legs; the carcinoid tumours were all of mid gut origin and had liver metastases at the time of presentation; all subsequently developed fibrotic heart disease; none had clinical features or evidence of autoantibodies associated with systemic sclerosis. The association of certain clinical features of carcinoid syndrome with cutaneous scleroderma seems to be more than fortuitous.
